MATTHEW WANAT to Stroke
This is a "connection" page, showing publications MATTHEW WANAT has written about Stroke.
Connection Strength
0.207
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.120
-
Novel oral anticoagulants: a review of new agents. Postgrad Med. 2013 Jul; 125(4):103-14.
Score: 0.055
-
Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with atrial fibrillation. J Am Pharm Assoc (2003). 2025 May-Jun; 65(3):102355.
Score: 0.031